Dimethyl fumarate - new measures to minimise leukoencephalopathy risk

Revised monitoring recommendations have been issued to reduce the risk of progressive multifocal leukoencephalopathy (PML) in patients with MS receiving dimethyl fumarate (Tecfidera).

Further information
View dimethyl fumarate drug record
Letter to healthcare professionals

A full blood count is now required every 3 months during treatment with dimethyl fumarate, and a baseline reference MRI should be performed before starting treatment.

If lymphocyte counts fall below 0.5 x109/L for more than 6 months, interruption of treatment should be considered. If treatment is stopped, patients should be monitored until lymphocyte levels return to normal. If treatment is continued, patients should be reminded to report symptoms of PML and the need for additional MRI should be considered. Treatment should be stopped immediately if PML is suspected.

PML is a rare but serious opportunistic infection caused by the John-Cunningham virus. Recommendations to reduce the risk of PML associated with dimethyl fumarate were initially introduced in April 2015 after a single fatal case was reported in a patient who had been receiving the drug for 4.5 years.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...